Clinical Trial Update: Roll-over Study to Allow Access to Certinib (LDK378) for Patients Who Are on Ceritinib Treatment in a Novartis-sponsored Study [Phase 4]

View source ↗

Summary

This is a rollover/compassionate-use style update allowing patients already on ceritinib to continue receiving the drug within a Novartis-sponsored Phase 4 stud…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alk-positive Malignancies
• Non-small Cell Lung Cancer

Drugs mentioned

• Ceritinib (Zykadia) (ceritinib)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: ALK Positive Malignancies | Phase 4 | Status: ACTIVE_NOT_RECRUITING